Roubaix Capital LLC lessened its position in shares of Stevanato Group S.p.A. (NYSE:STVN – Free Report) by 17.1% in the 3rd quarter, HoldingsChannel reports. The fund owned 328,858 shares of the company’s stock after selling 67,964 shares during the period. Stevanato Group accounts for about 2.7% of Roubaix Capital LLC’s portfolio, making the stock its 6th biggest holding. Roubaix Capital LLC’s holdings in Stevanato Group were worth $6,899,000 at the end of the most recent reporting period.
A number of other large investors also recently modified their holdings of the company. Wellington Management Group LLP acquired a new stake in shares of Stevanato Group in the 2nd quarter valued at $22,621,000. Ranger Investment Management L.P. purchased a new stake in shares of Stevanato Group during the 2nd quarter worth $21,438,000. Fenimore Asset Management Inc purchased a new stake in shares of Stevanato Group during the 3rd quarter worth $12,212,000. Confluence Investment Management LLC acquired a new position in shares of Stevanato Group during the second quarter worth $6,062,000. Finally, Lazard Asset Management LLC acquired a new position in shares of Stevanato Group during the first quarter worth $1,749,000.
Insider Activity at Stevanato Group
In other news, Director Donald E. Morel, Jr. acquired 25,000 shares of the company’s stock in a transaction on Friday, November 6th. The shares were bought at an average price of €13.07 per share, with a total value of €326,750.00. Following the completion of the acquisition, the director owned 62,424 shares in the company, valued at €815,881.68. This trade represents a 66.80% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director William J. Federici acquired 20,000 shares of the company’s stock in a transaction on Monday, November 9th. The shares were purchased at an average cost of €13.72 per share, for a total transaction of €274,400.00. Following the acquisition, the director owned 46,991 shares of the company’s stock, valued at approximately €644,716.52. The trade was a 74.10% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure.
Stevanato Group Stock Up 0.8%
Shares of NYSE:STVN opened at €15.37 on Wednesday. The firm has a 50 day simple moving average of €18.94 and a 200-day simple moving average of €17.91. Stevanato Group S.p.A. has a twelve month low of €12.05 and a twelve month high of €24.01. The company has a current ratio of 1.73, a quick ratio of 1.19 and a debt-to-equity ratio of 0.22. The company has a market capitalization of $4.65 billion, a PE ratio of 26.49, a P/E/G ratio of 1.60 and a beta of 0.80.
Stevanato Group (NYSE:STVN – Get Free Report) last posted its earnings results on Tuesday, November 3rd. The company reported €0.16 EPS for the quarter, missing analysts’ consensus estimates of €0.17 by (€0.01). The company had revenue of €326.06 million during the quarter. Stevanato Group had a net margin of 11.24% and a return on equity of 10.51%. On average, equities analysts predict that Stevanato Group S.p.A. will post 0.67 EPS for the current fiscal year.
Analysts Set New Price Targets
STVN has been the topic of several recent analyst reports. Weiss Ratings raised Stevanato Group from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, August 27th. UBS Group decreased their price target on Stevanato Group from $23.00 to $16.00 and set a “neutral” rating for the company in a report on Wednesday, November 4th. Citigroup lowered their price objective on Stevanato Group from $26.00 to $20.00 and set a “buy” rating for the company in a research report on Wednesday, November 4th. William Blair downgraded Stevanato Group from an “outperform” rating to a “market perform” rating in a report on Wednesday, November 4th. Finally, Deutsche Bank initiated coverage on Stevanato Group in a research report on Wednesday, October 7th. They set a “hold” rating on the stock. Two analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy”.
Read Our Latest Stock Report on STVN
Stevanato Group Company Profile
Stevanato Group is an Italian provider of drug-containment and drug-delivery solutions for the pharmaceutical, biotechnology and diagnostic industries. Founded in 1949 by Giovanni Stevanato, the company began as a glassmaking business and has expanded into a global supplier of products and services for the life sciences sector. The company makes primary packaging for injectable medicines, including glass vials, cartridges, syringes and ampoules. Its offerings also include ready-to-use containers, as well as services such as product development, analytical testing and packaging support.
Read More
- Five stocks we like better than Stevanato Group
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Want to see what other hedge funds are holding STVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stevanato Group S.p.A. (NYSE:STVN – Free Report).
Receive News & Ratings for Stevanato Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stevanato Group and related companies with MarketBeat.com's FREE daily email newsletter.
